Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

ARBs cut risk of CVD events in hypertension

Adding an angiotensin receptor blocker (ARB) to the treatment of patients with uncontrolled blood pressure reduces the risk of cardiovascular complications, a new trial has found.

The trial, of 3031 patients from Japan, found that adding valsartan reduced the risk of cardiovascular events by 45%, compared to non-ARB, non-ACE inhibitor treatment that lowered blood pressure by the same amount. The number of patients who needed to take valsartan to prevent a cardiovascular complication was 21.

But the Kyoto heart study found that the main difference between the treatments was a reduction in cases of angina and strokes over the four years of follow up. There was no significant difference in the numbers of heart attacks or in the development of heart failure. There was also no significant reduction in cardiovascular death or all-cause mortality.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say